Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies

NCT03363893 is registered in ClinicalTrials.gov with Carrick Therapeutics Limited as lead sponsor.

NCT NCT03363893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03363893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies
Lead sponsor
Carrick Therapeutics Limited
Phase
Phase 1/2
Overall status
Completed
Start date
November 14, 2017
Completion date
December 15, 2022
Enrollment
124 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies